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Rationale: Critical illness is characterized by lean tissue wasting,
whereas adipose tissue is preserved.Overweight andobese critically
ill patients may have a lower risk of death than lean patients,
suggestive of a protective role for adipose tissue during illness.
Objectives: To investigate whether adipose tissue could protectively
respond to critical illness by storing potentially toxic metabolites,
such as excess circulating glucose and triglycerides.
Methods: We studied adipose tissue morphology and metabolic
activity markers in postmortem biopsies of 61 critically ill patients
and 20 matched control subjects. Adipose morphology was also
studied in in vivo biopsies of 27 patients and in a rabbit model of
critical illness (n5 22).
Measurements and Main Results: Adipose tissue from critically ill
patients revealed a higher number and a smaller size of adipocytes
and increased preadipocytemarker levels as comparedwith control
subjects. Virtually all adipose biopsies from critically ill patients
displayed positive macrophage staining. The animal model demon-
strated similar changes. Glucose transporter levels and glucose
content were increased. Glucokinase expression was up-regulated,
whereas glycogen and glucose-6-phosphate levels were low. Acetyl
CoA carboxylase protein and fatty acid synthase activity were in-
creased. Hormone-sensitive lipase activity was not altered, whereas
lipoprotein lipase activity was increased. A substantially increased
AMP-activated protein kinase activity may play a crucial role.
Conclusions: Postmortem adipose tissue biopsies from critically ill
patientsdisplayeda largernumberof small adipocytes in responseto
critical illness, revealing an increased ability to take up circulating
glucose and triglycerides. Similar morphologic changes were pres-
ent in vivo. Such changes may render adipose tissue biologically
activeas a functional storagedepot forpotentially toxicmetabolites,
thereby contributing to survival.
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Critically ill patients requiring prolonged intensive care are
characterized by a profound decrease of lean body mass,
evoking weakness and impairing rehabilitation, whereas, para-
doxically, adipose tissue is preserved (1, 2). Remarkably, over-
weight (body mass index [BMI], 25–30 kg/m2) and obese (BMI,
30–40 kg/m2) critically ill patients have recently been shown to
have a lower risk of death than patients with a normal BMI
(3–5). Morbid obesity (BMI > 40 kg/m2), however, is an
independent risk factor for death in the intensive care unit
(ICU) (4). These observations suggest that adipose tissue may
play a protective role during severe illness in the intensive care
setting.
The primary metabolic role of adipose tissue is to store
excess energy as triglycerides. This excess energy mainly
originates from circulating lipids, which are taken up by adipo-
cytes via action of lipoprotein lipase (LPL). A much smaller
part of the stored triglycerides in adipocytes is de novo syn-
thesized from circulating carbohydrates through lipogenesis (6).
Critically ill patients suffer from dyslipidemia and hyper-
glycemia, partly due to increased hepatic lipogenesis (7)
and gluconeogenesis (8). The severity of these alterations is
associated with adverse outcome (9–11). Moreover, elevated
circulating glucose (12–14) levels as well as high levels of
triglycerides (15–17) can aggravate vital organ dysfunction
during critical illness. We hypothesized that adipose tissue can
respond to illness by increasing its storage properties for such
circulating toxic metabolites, whereby it may enhance the
chances of survival. To test this hypothesis, we obtained
abdominal subcutaneous and omental adipose tissue biopsies
from 61 nonsurviving critically ill patients with a BMI ranging
from 16.3 to 31.2 kg/m2, and compared these with biopsies from
20 matched control subjects undergoing elective abdominal
surgery. More specifically, we studied adipose tissue morphol-
ogy as well as its ability to take up and metabolize glucose and
triglycerides. In addition, we studied adipose tissue morpholog-
ical changes in response to critical illness in in vivo subcutane-
ous limb adipose tissue from 27 critically ill patients, and in the
controlled setting of an animal model.
Some of the results of this study have been previously
reported in the form of an abstract (18, 19).
METHODS
Patients
Patients were all enrolled in a large prospective, randomized, con-
trolled study on the effects of intensive insulin therapy on outcome of
AT A GLANCE COMMENTARY
What This Study Adds to the Field
Adipose tissue is substantially altered during critical illness,
with an increased number of newly formed adipocytes, and
is infiltrated by macrophages. These adipocytes have an
increased ability to store glucose and triglycerides, possibly
reducing detrimental effects of high levels of these circu-
lating metabolites.
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critical illness (20). The detailed protocol of the study has been
previously published (20). In brief, patients who had been randomly
assigned to conventional insulin therapy received insulin only when
glucose concentrations exceeded 215 mg/dl, resulting in mean blood
glucose of 157 mg/dl (hyperglycemia). Intensive insulin therapy tar-
geted blood glucose levels between 80 and 110 mg/dl, which resulted in
mean blood glucose of 110 mg/dl (normoglycemia). Glucose control in
each group was maintained according to protocol until ICU discharge
or death. Postmortem biopsy samples of abdominal subcutaneous and
omental adipose tissue were harvested within minutes after death from
61 long-stay patients of the 266 long-stay patients who died in the ICU,
during weekdays, after consent, and when sufficient technical support
was available. For postmortem tissue sampling, for academic purposes,
each patient or his/her legal representative consented upon admission,
via a hospital-wide information and consent procedure that requires
active opting-out when not consenting. Opting-out remained possible
until time of death. This strategy was approved by the K.U. Leuven
Institutional Ethical Review Board (internal identification number
ML 1820). The baseline and outcome characteristics of the critically
ill patients from whom postmortem adipose tissue biopsies were
collected are described in Table 1. From 27 long-stay patients, we
collected qualitative in vivo subcutaneous adipose tissue biopsies from
the vastus lateralis region on Day 15 of their ICU stay. The in vivo
biopsies were taken after specific written informed consent from the
patient or his/her legal representative. The baseline and outcome
characteristics of the critically ill patients from whom in vivo adipose
tissue biopsies were collected are described in the online supplement.
All baseline characteristics were comparable for the two insulin
treatment groups.
For comparison, we also collected abdominal subcutaneous and
omental adipose tissue biopsy samples from demographically matched
patients who were not critically ill, and who underwent elective
abdominal surgery for restorative rectal resection (ML 2707; see online
supplement). These patients provided written informed consent prior
to the procedure.
The protocols and all consent forms were approved by the K.U.
Leuven Institutional Ethical Review Board (internal identification
numbers ML 1820 and ML 2707). All tissue samples were snap frozen
in liquid nitrogen and stored at2808C until analysis.
Gene and Protein Expression
Messenger RNA was isolated and cDNA quantified in real time as
described previously (12). Data are expressed normalized to glyceral-
dehyde 3-phosphate dehydrogenase expression and as a fold change of
the mean of the control patients. A complete list of primers and probes
is provided in the online supplement. Western blots were performed as
described in the online supplement.
Glucose and Triglyceride Tissue Content
Spectrophotometric assays were used to quantify the tissue levels of
glucose, glucose-6-phosphate, glycogen, and glycerol levels, the latter
in Bligh-Dyer extracts of tissues (21).
Fatty Acid Synthase, Lipase, and AMP-activated Protein
Kinase Activity Assays
For fatty acid synthase (FAS) activity, reaction mix containing reduced
nicotinamide adenine dinucleotide phosphate, acetyl CoA, malonyl
CoA, and [2–14C]malonyl CoA was added to tissue homogenates.
After incubation and extraction of the fatty acids, incorporation of
[2–14C]malonyl CoA was analyzed by scintillation counting. The
kinase assay for AMP-activated protein kinase (AMPK) activity has
been previously described (22), and was determined by the amount of
32P incorporation into an AMPK substrate. The detailed protocol is
described in the online supplement. Total lipase activity was deter-
mined with the commercial Confluolip kit (Progen Biotechnik, Heidel-
berg, Germany).
Circulating Parameters
Serum levels of insulin were measured by ELISA (Invitrogen, Mer-
elbeke, Belgium). Serum triglyceride levels were measured by a spec-
trophotometric assay, as described previously here. Samples were all
run in duplicate.
Rabbit Model of Critical Illness
The experiment was performed in our previously validated rabbit
model of prolonged critical illness, which has shown to mimic the
characteristic endocrine, biochemical, and immunological disturbances
TABLE 1. CHARACTERISTICS OF PATIENTS FROM WHOM POSTMORTEM BIOPSIES WERE STUDIED
Conventional Insulin Intensive Insulin
Characteristics (n 5 33) (n 5 28) P Value
Male sex, no. 19 17 0.80
Age, yr* 64 6 17 70 6 11 0.14
BMI, kg/m2* 23.5 6 3.6 24.8 6 3.3 0.12
History of diabetes, no. 4 5 0.53
APACHE-II score on admission† 26 (22–35) 28 (20–32) 0.98
SOFA score on admission† 10 (7–14) 8 (5–12) 0.10
Blood glucose on admission, mg/dl* 167.5 6 73.7 174.5 6 75.9 0.71
Days in ICU† 10 (6–21.5) 10 (7–15.5) 0.95
Diagnostic group upon admission 0.69
Cardiovascular 3 2
Gastrointestinal or liver 4 1
Hematologic or oncologic 7 3
Neurologic 1 2
Renal 1 1
Respiratory 15 15
Other 2 4
Cause of death in ICU 0.37
Severe brain damage 2 0
Respiratory failure 13 13
Therapy resistant septic shock/cardiovascular collapse 8 6
Persistent MOF after septic or SIRS induced shock 10 9
CRP level on biopsy day, mg/L† 178 (61–235) 152 (73–268) 0.8
Time lag, time of death to biopsy preservation, min* 14.5 6 8.3 19.5 6 12.7 0.07
Definition of abbreviations: APACHE 5 Acute Physiology and Chronic Health Assessment Evaluation; BMI 5 body mass index;
CRP 5 C-reactive protein; ICU 5 intensive care unit; SOFA 5 Sequential Organ Failure Assessment (higher scores indicate more
severe illness); MOF 5 Multiple Organ Failure; SIRS 5 systemic inflammatory response syndrome.
* Data presented are mean 6 SD.
† Data presented are median (interquartile range).
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of human critical illness (23). For the purpose of this study, the
protocol was slightly modified. We sampled subcutaneous adipose
tissue biopsies before randomization and again after 7 days. Rabbits
were randomized into two groups: 7 sham-operated animals, and 15
critically ill animals. The detailed protocol is described in the online
supplement.
Adipocyte Morphology
For quantification of adipocyte size, sections were stained with
hematoxylin and eosin, and adipocyte size was determined by com-
puter image analysis. For macrophage evaluation, sections were stained
with a primary anti-macrophage antibody, and counterstained with
hematoxylin. Adipose tissue sections were evaluated in a blinded
fashion. A detailed protocol is described in the online supplement.
Statistical Analysis
We used analysis of variance and unpaired t test for normally
distributed data and the nonparametric Kruskal-Wallis and Mann-
Whitney U test when data appeared to be not normally distributed. We
used x2 test for comparison of proportions. We used Wilcoxon’s signed
ranked paired analysis for the rabbit data. The significance of corre-
lations was assessed by calculation of the Pearson (r) correlation
coefficient. P values of 0.05 or less were considered statistically
significant.
RESULTS
Adipocyte Morphology and Macrophage Staining
Adipocyte cell size of both subcutaneous and omental adipose
tissue of critically ill patients was smaller than that of healthy
control subjects. This was revealed by a smaller median cell area
(Figure 1A). The fraction of small adipocytes in postmortem
subcutaneous adipose tissue (defined as cell area below the 25th
percentile of those in healthy control subjects [400 mm2]) was
increased to 33.4% in biopsies from critically ill patients (P 5
0.008). A comparable amount (30.5%, ranging from 21.8 to
43.9%) of small adipocytes was observed in in vivo harvested
subcutaneous adipose tissue biopsies (n 5 27). In omental post-
mortem adipose tissue, 41.4% of the adipocytes in the critically ill
biopsies were small (defined as cell area smaller than the 25th
percentile of the healthy control subjects [500 mm2]), which was
significantly more than in control subjects (P , 0.003). Total
protein content per gram tissue was similar in critically ill and
control biopsies (see the online supplement). Gene expression
levels of perilipin, a protein coating the lipid droplet in adipo-
cytes, was lower in subcutaneous and omental postmortem
adipose tissue of critically ill patients than in control subjects
(Figure 1B). In contrast, protein levels of the pre-adipocyte
marker, preadipocyte factor (Pref)–1, was higher in biopsies from
critically ill patients than in control subjects (Figure 1C). We
stained sections of adipose tissue for the macrophage marker,
CD68 (Figure 1D). In both subcutaneous adipose tissue and
omental adipose tissue biopsies of healthy control subjects, two-
thirds stained negative, whereas, in one-third of the biopsies,
some positive staining was present. This was in sharp contrast
with the postmortem biopsies from critically ill patients, where
100% (subcutaneous adipose tissue, P, 0.0001) and 95% (omen-
tal adipose tissue, P , 0.0001) stained positive for CD68.
Furthermore, in two-thirds of the biopsies of critically ill patients,
Figure 1. Human adipocyte morphology in critical illness in postmortem biopsies (A–D) and paired in vivo analysis of adipocyte cell size in a rabbit
model of critical illness (E ). (A) Median adipocyte cell area, (B) mRNA adipose tissue (A.T.) levels of perilipin, (C ) protein A.T. levels of preadipocyte
factor (Pref)–1, (D) CD68 macrophage staining. Data boxes represent median and interquartile range; whiskers represent the 10th and the 90th
percentiles. White boxes represent healthy control subjects undergoing elective surgery (n 5 20); dark gray boxes represent critically ill patients who
received conventional insulin therapy (n 5 33); light gray boxes represent critically ill patients who received intensive insulin therapy (n 5 28). Lines
and P values indicate difference between healthy and conventionally treated critically ill patients. *Different from conventional insulin therapy (P <
0.05). A.U. 5 arbitrary units. (E ) Paired median adipocyte cell area in sham-treated healthy rabbits (n 5 7) and critically ill rabbits (n 5 15).
Subcutaneous A.T. biopsies were taken at Day 0 (before randomization) and after 7 days. At Day 7, A.T. biopsies from two healthy rabbits and eight
sick rabbits stained positive for macrophages. A.U. 5 arbitrary units; Subc. 5 subcutaneous.
Langouche, Vander Perre, Thiessen, et al.: Adipose Tissue during Critical Illness 509
the number of CD681 cells was high. CD681 staining was also
observed in the 27 in vivo subcutaneous limb adipose tissue
biopsies of prolonged critically ill patients. All of the 15 in vivo
biopsies of conventional patients stained positive for macro-
phages, and, in 73% of these, the number of positively staining
cells was high. From the 12 in vivobiopsies obtained from patients
under intensive insulin treatment, 11 stained positive for macro-
phages, and, in 50% of these, the number of positively staining
cells was high.
We also performed a control experiment in our rabbit model
of critical illness, in which we compared 15 ill rabbits with 7 sham-
operated rabbits. This model allowed us to sample adipose tissue
before and after 7 days of illness in the same animal. We could
demonstrate a decrease in median cell size in the ill rabbits
compared with the healthy rabbits (Figure 1E), whereas the total
weight of the isolated fat pad did not decrease (median weight,
4.1 g for both;P5 0.9), indicative of an increased cell number. We
also measured an increase in macrophage staining in the biopsies
from ill rabbits versus those from healthy rabbits on Day 7
(increase from 29% of biopsies with RAM111 staining in sham-
operated animals to 53% in ill rabbits).
Storage Properties of Adipose Tissue during Critical Illness
We first studied the ability of the adipose tissue to take up and
metabolize glucose into fatty acids in patients with prolonged
critical illness as compared with control subjects. In postmortem
subcutaneous and omental adipose tissue of critically ill pa-
tients, mRNA and protein levels of the insulin-independent
glucose transporters, GLUT1 and GLUT3, but not the insulin-
dependent GLUT4, were strongly elevated (see Figures 2A–2B
and the online supplement). The tissue content of glucose in
postmortem subcutaneous and omental adipose tissue of criti-
cally ill patients was higher than in control subjects (Figure 2D),
but was lowered by intensive insulin therapy. These differences
in the adipose tissue glucose content among the groups mim-
icked the differences in plasma glucose (Figure 2E).
When glucose enters the cell, it is phosphorylated by the
enzyme, hexokinase, to glucose-6-phosphate, which can, in turn,
Figure 2. Glucose uptake in postmortem adipose tissue (A.T.) of critically ill patients. Human A.T. levels of (A) protein of GLUT1 and GLUT3, (B)
mRNA of GLUT4, (C ) mRNA of glucokinase, (D) tissue levels of glucose, and (E ) mean daily plasma glucose levels. Data boxes present median and
interquartile range; whiskers represent the 10th and the 90th percentiles.White boxes represent healthy control subjects undergoing elective surgery
(n 5 20); dark gray boxes represent critically ill patients who received conventional insulin therapy (n 5 33); light gray bars represent critically ill
patients who received intensive insulin therapy (n 5 28). Lines and P value indicate difference between healthy and conventionally treated critically
ill patients. *Different from conventional insulin therapy (P < 0.05); **different from conventional insulin therapy (P < 0.01). A.U. 5 arbitrary units;
Subc. 5 subcutaneous.
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be stored as glycogen, or further metabolized to pyruvate. In
healthy control subjects, we documented very low glucokinase
gene expression levels compared to the much higher levels in
postmortem subcutaneous adipose tissue of critically ill patients
(Figure 2C). Hexokinase 1 and 2 expression in the critically ill
was not different from control subjects (see the online supple-
ment). The tissue levels of glucose-6-phosphate and of glycogen
were hardly detectable in postmortem subcutaneous and omen-
tal adipose tissue of both critically ill patients and control
subjects.
Because, in the adipose tissue biopsies, glucose was not
stored as glycogen, we studied lipogenesis as the alternative
metabolic destiny of glucose. When glucose is metabolized into
fatty acids, the glycolytic end product, pyruvate, is metabolized
to acetyl CoA, which is subsequently turned into malonyl CoA
by the enzyme, acetyl CoA carboxylase (ACC). In postmortem
subcutaneous adipose tissue of critically ill patients, total levels
of ACC were indeed several fold higher than in healthy control
subjects (Figure 3A). In addition, the enzymatic activity of FAS,
another lipogenic enzyme, was strongly up-regulated (Figure
3B). Expression of stearoyl CoA desaturase, involved in the
biosynthesis of monounsaturated fatty acids, was also higher in
postmortem subcutaneous adipose tissue of critically ill patients
(Figure 3C). Similar changes in these lipogenic enzymes were
observed in the omental adipose tissue biopsies of critically ill
patients (Figures 3A–3C).
The other important metabolic storage process that takes
place in adipose tissue is lipolysis. LPL is responsible for
hydrolysis and uptake of circulating triglycerides. On the other
hand, activated hormone-sensitive lipase (HSL) is the rate-
limiting enzyme in the hydrolysis and the release of stored adipose
triglycerides back into the bloodstream. Circulating triglyceride
levels were increased in critical illness (Figure 4B). In both
omental and subcutaneous postmortem adipose tissue homoge-
nates of critically ill patients, levels of activated (Ser563 phos-
phorylated) HSL remained equal compared with that of healthy
control subjects (Figure 3D). In contrast, protein levels of LPL
were increased several fold in both omental and subcutaneous
adipose tissue homogenates of critically ill patients (Figure 3E).
Total lipase activity was also increased several fold in postmor-
tem omental and subcutaneous adipose tissue homogenates
of critically ill patients (Figure 3F), and correlated with LPL
levels (r5 0.279,P5 0.03 in omental adipose tissue), but not with
phosphorylated HSL.
Figure 3. Lipogenesis and lipolysis in postmortem adipose tissue (A.T.) of critically ill patients. Human A.T. levels of (A) acetyl CoA carboxylase
protein, (B) fatty acid synthase activity, (C ) stearoyl CoA desaturase mRNA, (D) phospho(Ser563) hormone-sensitive lipase protein, (E) protein of
lipoprotein lipase, and (F) lipase activity. Data boxes present median and interquartile range; whiskers represent the 10th and the 90th percentiles.
White boxes represent healthy control subjects undergoing elective surgery (n 5 20); dark gray boxes represent critically ill patients who received
conventional insulin therapy (n 5 33); light gray bars represent critically ill patients who received intensive insulin therapy (n 5 28). Line and P value
indicate difference between healthy and conventionally treated critically ill patients. *Different from conventional insulin therapy (P , 0.05). A.U. 5
arbitrary units; Subc. 5 subcutaneous.
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Impact of Intensive Insulin Therapy on Adipose Tissue
Morphology and Studied Metabolic Pathways
Critically ill patients in both the conventional and the intensive
insulin treatment arms revealed elevated circulating glucose
and insulin levels as compared with control subjects, typical for
the insulin resistance associated with severe illness. Blood
glucose levels were lower (Figure 2E), as per protocol, and
circulating insulin levels were higher in intensive insulin–treated
patients, who received higher doses of insulin as compared with
patients in the conventional insulin group (Figure 4B).
The intensity of insulin therapy during critical illness, how-
ever, only had a relatively small effect on adipocyte morphology
and on the studied storage parameters tested. Intensive insulin
therapy reduced the incidence of positive macrophage staining in
subcutaneous adipose tissue (from 64 to 53% in omental, and
from 66 to 27% in subcutaneous adipose tissue). Intensive insulin
therapy reduced the glucose content in postmortem adipose
tissue, as well as the expression levels of Pref-1 and GLUT-3 in
omental adipose tissue (Figures 1C and 2A), elevated the
expression levels of GLUT-4 in omental adipose tissue (Figure
2B), and increased the expression levels of glucokinase in post-
mortem subcutaneous and omental adipose tissue (Figure 2C).
Mechanism behind Altered Substrate Handling
The energy-sensing enzyme, AMPK, usually activated by a high
AMP:ATP ratio, was clearly activated in subcutaneous and
omental adipose tissue of critically ill patients as compared with
control subjects (Figure 4A). AMPK increases glucose uptake
and glycolysis, but can also inactivate ACC by phosphorylation.
Indeed, protein levels of phosphorylated ACC were increased in
postmortem adipose tissue of critically ill patients (in subcutane-
ous adipose tissue: median [interquartile range], 6.8 [2.8–11.9]
in critically ill patients versus 1 [0.4–3.3] in control subjects;
P5 0.0002; in omental adipose tissue: 5.9 [2.7–12.7] in critically ill
patients versus 1.4 [0.7–3.1] in control subjects; P 5 0.04). The
ratio of phosphorylated ACC to total ACC levels was not
different between critically ill patients and control subjects
(P5 0.6 for subcutaneous adipose tissue and P5 0.5 for omental
adipose tissue).
One might hypothesize that the artificial enteral and paren-
teral feeding used for critically ill patients may affect lipogenesis
and lipolysis. Although the sum of daily enteral and parenteral
amounts of carbohydrate and lipids at no time exceeded the
required daily amounts (Figure 4C), the ICU patients included in
this study all received at least partial parenteral feeding during
ICU stay, due to the type and severity of illness (patients from
whom biopsies were studied were all nonsurvivors, with high on-
admission Acute Physiology and Chronic Health Assessment
Evaluation II scores). However, the studied parameters in sub-
cutaneous and omental adipose tissue did not correlate with the
daily parenteral or total caloric intake, except for FAS activity in
omental adipose tissue, which correlated with the mean total
caloric intake (r2 5 0.251) (see the online supplement).
The patient population from which we were able to collect
postmortem adipose tissue biopsies has a mean BMI of 25,
Figure 4. Mechanism behind altered substrate handling in postmortem adipose tissue (A.T.) of critically ill patients. (A) Human A.T. activity levels of
AMP-activated protein kinase (AMPK), (B) serum insulin and serum triglyceride levels on biopsy day, (C) daily intake of enteral and parenteral
feeding during intensive care unit (ICU) stay. Data boxes represent median and interquartile range; whiskers represent the 10th and the 90th
percentiles. Open boxes represent healthy control subjects undergoing elective surgery (n 5 20); light gray boxes represent critically ill patients who
received conventional insulin therapy (n 5 33); dark gray boxes represent critically ill patients who received intensive insulin therapy (n 5 28). Lines
and P value indicate difference between healthy and conventionally treated critically ill patients. *Different from conventional insulin therapy (P <
0.05). (C ) Gray bars represent the daily intake of parenteral feeding in critically ill patients who received conventional insulin therapy (light gray; n5
33) and intensive insulin therapy (dark gray; n 5 28), and black bars represent the daily enteral intake. The upper panel represents the administered
carbohydrates; the lower panel represents the administered lipids. Data are presented as mean total daily (24-h) intake on day of admission, Day 5,
Day 10, and last day of ICU stay. EN 5 enteral; PN 5 parenteral; Subc. 5 subcutaneous.
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ranging from 16.3 to 31.2. The tested 61 biopsies were pre-
dominantly from normal to overweight patients: 33 (54%) of
the patients had a normal BMI, 22 (36%) were overweight, and
only 3 (5%) were obese. Only omental median adipocyte cell
size showed a biologically relevant correlation with BMI. This
suggests that adipocytes in either normal or overweight criti-
cally ill patients may act identically.
DISCUSSION
Our data suggest that adipose tissue is substantially altered during
critical illness, with an increased number of newly formed
adipocytes and macrophage infiltration. The larger number of
small adipocytes appear to have an increased ability to take up
and metabolize glucose and store triglycerides, a process in which
an increased activity of the energy-sensing enzyme, AMPK, could
partially play a role. Taking into account the clear association
between both hyperglycemia and dislipidemia and mortality
observed in critical illness, these alterations may present an
adaptive and protective response.
We observed a smaller median adipocyte cell size and an
increase in number of small adipocytes in critically ill patients,
indicating a higher number of newly formed adipocytes. Al-
though its function is not unequivocally clear, the observed
elevation in the preadipocyte marker, Pref-1, also may be in-
dicative of an up-regulated differentiation from mesenchymal
stem cells into preadipocytes, and further into full functional
adipocytes. However, Pref-1 has not only been suggested to be
a potentiator of adipogenesis in mesenchymal cells (24, 25), but
also to maintain the undifferentiated state of preadipocytes (26,
27). As we observed a higher number of small-sized adipocytes
together with higher levels of Pref-1, our results could be inter-
preted as increased adipogenesis.
The high number of CD68 positive–stained cells in all studied
adipose tissue biopsies of critically ill patients, obtained from
both the subcutaneous and the omental site, postmortem and
in vivo, is striking. CD68 is recognized to be a specific macrophage
marker (28). Macrophage accumulation in adipose tissue has
been demonstrated in obesity (29, 30), and systemic hypoxia has
been associated with increased inflammation in adipose tissue
(31). Several reasons for macrophage accumulation in adipose
tissue of obese people have been proposed. It has been suggested
that hypertrophic or expanding adipocytes may produce chemo-
tactic signals, leading to macrophage recruitment in an attempt to
limit adipose tissue expansion (32–34). The other suggested
mechanism involves oxidative stress in the endothelium due to
increased glucose delivery. Endothelial injury in the adipose
tissue could attract inflammatory cells, such as macrophages,
further exacerbating local inflammation (35). Why critical illness
is associated with increased infiltration of macrophages is not
clear. Unlike in otherwise healthy obese people, we observed
smaller adipocytes during critical illness. Only rarely did we
observe large necrotic adipocytes surrounded by foaming mac-
rophages. The hyperglycemic environment of critical illness,
which has been shown to evoke endothelial injury (12), may play
a role. Indeed, patients in the conventional insulin arm revealed
more pronounced macrophage infiltration than patients in the
intensive insulin arm. However, expanding preadipocytes have
also been shown to produce chemotactic signals (36). In addi-
tion, macrophages may also originate from transdifferentiation of
preadipocytes into macrophage-like cells (37). Hence, the mac-
rophage accumulation in critical illness could be, in part, a conse-
quence of increased adipogenesis. Studies on the acute phase of
critical illness showed high levels of inflammatory markers, but
unaltered macrophage markers (38, 39), suggesting that the
macrophage accumulation that we observe is not part of the
acute stress response, but part of the complex hypermetabolic
condition of prolonged critical illness.
The larger number of small adipocytes appeared to have an
increased ability to take up and metabolize glucose into fatty
acids and to take up and store circulating triglycerides. Adipose
tissue normally takes up glucose through the insulin-dependent
glucose transporter, GLUT4 (40). We have now observed that the
insulin-independent glucose transporters, GLUT1 and GLUT3,
in adipose tissue were highly up-regulated during critical illness.
This may evoke an increased influx of glucose into adipose tissue.
Indeed, these high-affinity transporters have a Km below the
observed range of blood glucose in the critically ill, so an increase
in cell surface expression will affect the rate of glucose uptake into
the cells. This increase in glucose transporters might be triggered
by metabolic stress, such as cellular hypoxia, but also by hyper-
glycemia, insulin, or cytokines (41–43). Once transported into the
cell, glucose becomes phosphorylated to glucose-6-phophate by
hexokinase. We measured an increased expression of the low-
affinity glucokinase, but not of the high-affinity hexokinase I and
II. In contrast to hexokinase I and II, glucokinase is not inhibited
by its end product, glucose-6-phophate (41), whereby it contrib-
utes to rapid phosphorylation and trapping of glucose into the
cell. We measured only very low levels of glucose-6-phophate and
glycogen in the adipose tissue, indicating that glucose-6-phophate
is further metabolized. In normal conditions, glucose-6-phophate
would be oxidized in the Krebs cycle. The increased activity of the
lipogenic enzymes, ACC, FAS, and stearoyl CoA desaturase, in
the critically ill, however, may point to an increased metaboliza-
tion of glucose into fatty acids (44).
Although adipose tissue can synthesize free fatty acids
de novo, free fatty acids for lipid storage are preferentially
provided by LPL-mediated hydrolysis of circulating triglyceride-
rich lipoproteins. We could indeed demonstrate that adipose
tissue of critically ill patients showed a markedly increased LPL
protein level and lipase activity. Furthermore, LPL is an impor-
tant marker for adipocyte differentiation with increased LPL
expression when preadipocytes differentiate (45). Contrary to the
uptake of circulating triglycerides, HSL will hydrolyze and
release stored triglycerides back into the circulation. In the
studied biopsies from critically ill patients, we observed no
alteration in the level of activated HSL.
All the studied ICU patients received intravenous feeding
during ICU stay. Although the sum of enteral and parenteral
feeding components did not exceed the reference daily intake
(46), one could expect intravenously administered glucose and
lipids to cause increased lipogenesis or lipolysis in adipose tissue.
However, we did not observe a correlation between the mean
total or intravenous caloric intake and the studied glycolytic,
lipogenic, and lipolytic parameters, which appears to exclude
a prominent role of artificial feeding in explaining our observa-
tions. In addition, it has been shown previously that, as compared
with hepatic lipogenesis, human adipose tissue lipogenesis is less
responsive to dietary carbohydrates (47, 48).
A likely explanation for the observed shift in metabolization is
the hypoxic condition of critical illness. Critically ill patients
suffer from reduced oxygen pressure and oxygen blood content,
causing cellular hypoxia in different tissues (49). The cellular
pathways activated by hypoxic stress, such as the hypoxia-
inducible factor and AMPK pathway, shut down energy-consum-
ing pathways that are not acutely needed for cell survival.
Activation increases the uptake of glucose and glycolysis, result-
ing in pyruvate production (50, 51), but, in addition, HSL activity
is attenuated (52) and fatty acid uptake is increased (53, 54). We
clearly demonstrated increased AMPK activity in adipose tissue
of critically ill patients. A lower oxygen availability in adipose
tissue during critical illness may, thus, not only stimulate uptake
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of glucose, but also impair complete glucose oxidation, with
a shift to fatty acid synthesis. On the other hand, this mechanism
may attenuate hydrolysis of stored triglycerides, but stimulate
uptake of circulating fatty acids. Unfortunately, we were not able
to quantify possible hypoxia in the adipose tissue; thus, these
conclusions remain speculative. The high levels of circulating
insulin that are present in critically ill patients are also a possible
trigger for increased metabolization of glucose into fatty acids
(11). Insulin action in adipose tissue indeed involves stimulation
of glucose uptake, increase of glucokinase expression, and
stimulation of FAS expression and activity (41, 55, 56). Insulin
has been shown to reduce lipid oxidation by increasing intracel-
lular glucose flux (57). Insulin inhibits HSL activity, but stimu-
lates LPL levels and activity, thereby reducing hydrolysis of
stored triglycerides and increasing uptake of circulating triglyc-
erides (58–60). In addition, small-sized adipocytes have been
demonstrated to be more insulin sensitive and display increased
lipogenesis (61–63). The studied patients were all enrolled in
a large, randomized, controlled trial on glycemic control in the
medical ICU (20). Patients under intensive insulin therapy
received high doses of insulin to maintain normal blood glucose
levels, whereas patients who had been randomly assigned to
conventional insulin therapy received insulin only when glucose
concentrations exceeded 215 mg/dl. Although patients under
intensive insulin therapy received much higher doses of insulin
throughout the stay in the ICU, circulating insulin levels were not
that different. We demonstrated earlier that this is primarily due
to a lowered endogenous insulin production in the intensive
insulin therapy group, as well as an effect on insulin sensitivity (64,
65). The clearly elevated circulating insulin levels in both insulin
therapy groups may explain the minor differences in the meta-
bolic activity of the adipose tissue. A third possible mediator in
the observed changes might be the typical uniform suppression of
the neuroendocrine axes in prolonged critical illness (66). Indeed,
thyroid-stimulating hormone normally stimulates release of free
fatty acids from adipose tissue, and growth hormone reduces
adipocyte differentiation, triglyceride synthesis, and LPL activity
(67), but the pulsatile release of both hormones becomes sup-
pressed in prolonged critical illness. In addition, the inhibition of
the melanocortin system can promote lipid uptake and triglycer-
ide synthesis in adipose tissue (68). Thus, a single cause of the
altered metabolism in adipose tissue of critically ill patients is not
very likely, and a complex interplay of different affected path-
ways can be inferred.
Two important limitations of this study should be highlighted.
The tissue biopsies used for the metabolic study were obtained
from nonsurviving critically ill patients only, which may have
induced a bias due to the potential confounding effects of agonal
hypoxia. However, a previous study on phosphorylated signaling
molecules (64), and the observation that the AMPK enzyme in
liver samples from the same patients was not affected by illness
(unpublished observations), argues against such bias. In addition,
in the small set of in vivo subcutaneous adipose tissue biopsies
from patients with prolonged critical illness, we observed the
same morphological changes and macrophage staining pattern as
in the postmortem biopsies. Furthermore, we demonstrated
a reduction in adipocyte cell size and an increase in macrophage
staining in paired in vivo adipose tissue biopsies from critically ill
rabbits, very comparable to what we observed in the human
biopsies. A second limitation of the study is that the tested
biopsies were predominantly from normal and overweight pa-
tients; thus, we cannot extrapolate the results to obese critically ill
patients. Indeed, adipose tissue from non–critically ill obese
individuals markedly differs from that of lean subjects (e.g., with
regard to inflammation, adipokine expression, and macrophage
infiltration). However, when we compared lean subjects with
overweight patients, we found no correlation between the tested
parameters and BMI, except for cell size, and for this parameter
the association was also present in the healthy control subjects.
This suggests that adipocytes, in either normal or overweight
critically ill patients, appear to act identical in response to the
stress of illness, and that it may be merely the larger total fat depot
that might explain the lower mortality in overweight patients
versus patients with a normal BMI (3–5). However, based on
some contradictory studies in which a higher mortality was
already observed in obese critically ill patients (69–71), it appears,
as yet, unclear at what point a higher BMI switches from being
protective to malignant.
In conclusion, adipose tissue is substantially altered during
critical illness, with an increased number of newly formed
adipocytes and macrophage infiltration observed in in vivo– and
postmortem-harvested biopsies of patients, as well as in an animal
model. The larger number of small adipocytes appears to have an
increased ability to take up circulating glucose and triglycerides,
although this was only studied in postmortem biopsies. Such
changes may render adipose tissue biologically active as a func-
tional storage depot for these possibly toxic metabolites during
critical illness, thereby contributing to survival. Hypothetically,
this protective reaction may be more pronounced in critically ill
patients with a larger fat depot, but whether the observed changes
are also present in adipose tissue from obese and morbidly obese
patients needs further thorough investigation.
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